Knockout screening with Sanger arrayed genome-wide CRISPR libraries
About this webinar
We present the first genome wide, arrayed guide RNA screening libraries for CRISPR-Cas9. These libraries have been designed to cover 17166 human and 20430 mouse genes. To test the efficiency, we selected gRNAs targeting genes from the GPI anchor protein pathway. We observed that over 95% of these gRNAs successfully induced DNA cleavage and consequently gene loss of function. These libraries offer the prospect for performing high-throughput screens for genes of considerable scientific and therapeutic value in mouse and human cells.
Emmanouil Metzakopian, PhD
WTSI Career Development Fellow PDUK Senior Research Fellow
Wellcome Trust Sanger Institute
Dr. Metzakopian is a research fellow at Wellcome Trust Sanger Institute, where he focuses on identifying genes which confer resistance to chemotherapy drugs in embryonic stem cells and to oxidative stress agents in dopamine neurons.
Shawn Shafer, PhD
Advanced Genomics Market Segment Manager
MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany
Dr. Shafer leads a team responsible for product development of MilliporeSigma’s RNAi and genome editing portfolios. He orchestrated the creation of Sigma-Aldrich’s CRISPR collection of reagents.
This webinar is supported by Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $130 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada.